Company Profile for Aeolus Pharmaceuticals, Inc.
18 Février 2011 - 4:40PM
Business Wire
Aeolus Pharmaceuticals is developing a new class of catalytic
antioxidant compounds that protects healthy tissue from the
damaging effects of radiation. Its first compound, AEOL 10150, is
being developed for oncology indications, where it is used in
combination with radiation therapy. It is also being developed,
with funding by the US Government, as a medical countermeasure
against chemical and radiological weapons, where its initial target
indications are as a protective agent against the effects of acute
radiation syndrome and delayed effects of acute radiation exposure.
Aeolus’ strategy is to leverage the substantial investment in
toxicology, manufacturing, and preclinical and clinical studies
made by US Government agencies in AEOL 10150 to efficiently develop
the compound for use in oncology. For more information, please
visit Aeolus’ corporate website at www.aeoluspharma.com.
Company:
Aeolus Pharmaceuticals, Inc.
Headquarters Address:
26361 Crown Valley Parkway, Suite 150 Mission Viejo, CA 92691
Main Telephone:
949-481-9820
Ticker:
AOLS(OTCBB)
Type of Organization:
Public
Industry:
Biotechnology
Key Executives:
CEO: John McManus
CFO: Russell Skibsted
Chairman: David Cavalier
Investor Relations
Contact:
Russell Skibsted
Phone:
949-481-9825
Email:
russell@aolsrx.com
Aeolus Pharmaceuticals (CE) (USOTC:AOLS)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Aeolus Pharmaceuticals (CE) (USOTC:AOLS)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
Real-Time news about Aeolus Pharmaceuticals Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Aeolus Pharmaceuticals, Inc.